CD83 and rheumatoid arthritis: According to previous reports describing the properties of TolDCs derived from healthy donors (31, 43), MPLA-tDCs from RA patients showed reduced expression of co-stimulatory molecule CD86, the coactivator CD40, and the maturation marker CD83, as well as high expression of MHC class II, similar to mDCs.